Bystricky Branislav, Jurisova Silvia, Karaba Marian, Minarik Gabriel, Benca Juraj, Sedlácková Tatiana, Tothova Lubomira, Vlkova Barbora, Cierna Zuzana, Janega Pavol, Manasova Denisa, Gronesova Paulina, Pindak Daniel, Mardiak Jozef, Celec Peter, Mego Michal
Second Department of Medical Oncology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
Department of Oncology, Faculty Hospital Trencin, Trencin, Slovakia.
Anticancer Res. 2017 Apr;37(4):1787-1791. doi: 10.21873/anticanres.11512.
Cancer increases the risk of venous thromboembolism (VTE) and circulating tumor cells (CTCs) are associated with an increased risk of VTE and, thus, with increased D-dimers as a product of fibrinolysis. Tissue plasminogen activator (tPA) is one of the key enzymes in the fibrinolytic pathway. Its activity is crucial in maintaining the balance between blood coagulation and fibrinolysis. This study aimed to analyze the association between CTCs and tPA in patients with primary breast cancer before surgery.
This prospective study included 110 patients in whom CTCs were detected by quantitative reverse transcription polymerase chain reaction targeted at epithelial (CK19) or epithelial-mesenchymal transition (EMT)-associated genes[TWIST1, SNAI1, SNAI2, zinc finger E-box-binding homeobox 1 (ZEB1), forkhead box protein C2 (FOXC2)]. Plasma tPA protein was detected using enzyme-linked immunosorbent assay (ELISA).
CTCs were detected in 31 (28.2%) patients. There was no association between plasma tPA and CTCs. Although on average, higher levels of tPA were detected in patients with CTCs expressing EMT-associated genes, this difference did not reach statistical significance. There was no association of plasma tPA with any of the observed patient or tumor characteristics.
Even though the blood coagulation pathway may be activated in more aggressive disease related to an elevated CTC count, in this study, we did not find any association between CTCs and plasma concentrations of tPA.
癌症会增加静脉血栓栓塞（VTE）的风险，循环肿瘤细胞（CTC）与VTE风险增加相关，因此与作为纤维蛋白溶解产物的D - 二聚体升高有关。组织纤溶酶原激活物（tPA）是纤维蛋白溶解途径中的关键酶之一。其活性对于维持血液凝固和纤维蛋白溶解之间的平衡至关重要。本研究旨在分析原发性乳腺癌患者术前CTC与tPA之间的关联。
这项前瞻性研究纳入了110例患者，通过针对上皮（CK19）或上皮 - 间质转化（EMT）相关基因[TWIST1、SNAI1、SNAI2、锌指E盒结合同源框1（ZEB1）、叉头框蛋白C2（FOXC2）]的定量逆转录聚合酶链反应检测CTC。使用酶联免疫吸附测定（ELISA）检测血浆tPA蛋白。
31例（28.2%）患者检测到CTC。血浆tPA与CTC之间无关联。尽管平均而言，在表达EMT相关基因的CTC患者中检测到较高水平的tPA，但这种差异未达到统计学意义。血浆tPA与任何观察到的患者或肿瘤特征均无关联。
尽管在与CTC计数升高相关的侵袭性更强的疾病中凝血途径可能被激活，但在本研究中，我们未发现CTC与血浆tPA浓度之间存在任何关联。
